Early access program offers investigational meningioma treatment
NCT ID NCT07497984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program gives eligible patients with meningioma access to the investigational drug ITM-11 before it is officially approved. The treating doctor decides if the possible benefits outweigh the risks. The program is only available in certain countries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Drug combo aims to shrink NF2 tumors and save hearing
- Radiation's hidden toll on the brain: new study maps cognitive changes to protect patients
- New combo aims to stall aggressive brain tumors when surgery and radiation fail